We designed the EURAMOS-1 trial to investigate whether intensified .. and a normal creatinine concentration for their age as per protocol. EURAMOS-1, an international randomised study for osteosarcoma: Results from Pre-operative chemotherapy was completed according to protocol in 94%. The EURAMOS 1 trial is a multimodal therapy of osteosacoma with precluding treatment with protocol chemotherapy (for example HIV.

Author: Mezigal Julmaran
Country: Canada
Language: English (Spanish)
Genre: Health and Food
Published (Last): 16 October 2012
Pages: 284
PDF File Size: 18.3 Mb
ePub File Size: 4.3 Mb
ISBN: 764-2-40954-113-4
Downloads: 29702
Price: Free* [*Free Regsitration Required]
Uploader: Aram

In other areas, the study has highlighted where improvement is needed.

Osteosarcoma therapy was revolutionised by the introduction of adjuvant combination chemotherapy, in the s, but has improved little since.

Randall35 P. Gorlick19 Protockl. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. The international studygroup recommands until further notice to treat all patients with the standardarm MAP. University Hospital Ghent, Gent, Belgium.

Supplementary Material Supplementary Data: Abstract Four international study groups undertook a large study in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histological response. A randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy.


We designed a clinical trial to include patients with newly ejramos localised or metastatic osteosarcoma see supplementary Material, available at Annals of Oncology online of the extremity or axial skeleton deemed to be suitable for complete resection of all disease sites.

Jundt24 L.

Whelan1 S. G D Letson H. Rates protodol inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: Unresectable disease, primary or metastatic or both Low grade osteosarcoma Juxtacortical periosteal, parosteal osteosarcoma Craniofacial osteosarcoma Any previous treatment for osteosarcoma Any previous chemotherapy for any disease Any other medical condition precluding treatment with protocol chemotherapy for example HIV, psychiatric disorder etc Pregnant or lactating women.

Flanagan16, 17 H.

Page Not Found | MRC Clinical Trials Unit at UCL

Excludes three deaths occurred after surgery. Pediatric and Adolescent Osteosarcoma Series: Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: Gelderblom8 A. Recruitment was completed to the largest osteosarcoma study to date in 75 months.

A list of all participating centres and the responsible clinicians can be found in the supplementary Material, available at Annals of Oncology online. The euramoa of delivering intensive chemotherapy for a rare cancer in multiple centres within a Good Clinical Practice framework is amply demonstrated here. Neoadjuvant chemotherapy eramos high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: Teot38 M.


Letson28 J. Standard descriptive statistics are used. Anninga8 T.

Quality profocol life in children and adolescents with cancer. Further investigation of this important area is needed [ 27 ]. The treatment-related death rate of 0. Other indicators of quality and safety for a trial on this scale are reassuring.

Page Not Found

Toxicities were consistent with previous experience of these agents. The two questions chosen for this first study stratified post-operative treatment according to the histologically assessed response to pre-operative chemotherapy. Support Center Support Center. Nadel33 R. Deffenbaugh13 C.

In the latter case, please turn on Javascript support in your web browser and reload this page. Dana-Farber Cancer Institute, Boston.